



CHANGES OF MANAGEMENT BOARD

Greifswald – 1st April 2021

CHEPLAPHARM is delighted to announce an addition to its board of management.

With effect of April 1st, 2021 Dr. Keyarasch “Kia” Parssanedjad, M.D. joins the company’s management board as Chief Corporate Investment Officer (CIO).

Dr. Parssanedjad is an entrepreneurial healthcare leader, who has more than 15 years of hands-on experience in both building, managing as well as investing into innovative, high-growth healthcare and life science businesses.

Dr. Parssanedjad joins CHEPLAPHARM from McKinsey&Company, where he has been a co-leader of McKinsey’s global Leap practice in healthcare and life sciences focussing on business building with leading global clients. Previously, he held leadership roles at Merck Group. Dr. Parssanedjad is a trained physician and obtained his medical degree in the field of cancer research /gene therapy.

With this addition, CHEPLAPHARM further strengthens its management board by building on its core competence of corporate investments.

About CHEPLAPHARM

CHEPLAPHARM is a pharmaceutical company headquartered in Greifswald, Germany, offering branded and niche products in more than 120 countries worldwide. The family-owned company specializes in selected active substances and indications and focuses on an international buy-and-build strategy. Working closely with its business partners, CHEPLAPHARM achieves sustainable annual growth rates. CHEPLAPHARM has been one of the fastest-growing pharmaceutical companies in Europe.

Please refer to www.cheplapharm.com for additional information.

Press office:

CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | [presse\(at\)cheplapharm.com](mailto:presse(at)cheplapharm.com)